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	 A	novel	series	of	morpoline	 linked	 thiazolidione	hybrid	molecules	 targeting	bacterial	enoyl
acyl	carrier	protein	(Enoyl‐ACP)	reductase	were	designed	and	synthesized	 through	a	 three
step	 reaction	 protocol,	 which	 involves	 simple	 reaction	 setup	 and	 moderate	 reaction
conditions.	The	synthesized	molecules	were	characterized	with	FT‐IR,	1H	NMR,	13C	NMR	and
HRMS	 techniques.	 In	 vitro	 susceptibility	 tests	 against	 some	 Gram	 positive	 (Staphylococcus
aureus	 and	Bacillus	subtilis)	and	Gram	negative	bacteria	 (Escherichia	coli	and	Pseudomonas
aeruginosa)	 gave	 highly	 promising	 results.	Most	 of	 the	molecules	were	 found	 to	 be	 active
against	the	tested	bacterial	strains.	The	most	potent	molecule	(S2B7)	gave	MIC	value	of	2.0
µg/mL	 against	 Escherichia	 coli	 that	 was	 better	 than	 the	 reference	 drug	 streptomycin.
Structure	activity	relationship	showed	nitro	and	chloro	groups	are	crucial	 for	bioactivity	 if
present	 at	 meta	 position	 of	 arylidene	 ring	 in	 designed	 molecules.	 Molecular	 docking
simulations	against	multiple	targets	showed	that	the	designed	molecules	have	strong	binding
affinity	 towards	 Enoyl‐ACP	 reductase.	 Binding	 affinity	 of	 ‐8.6	 kcal/mol	 was	 predicted	 for
S2B7.	Van	der	Waals	forces,	hydrogen	bonding	and	hydrophobic	interactions	were	predicted
as	the	main	forces	of	interaction.	
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1.	Introduction	
	
With	 time,	 new	 classes	 of	 antimicrobial	 drugs	 were	
discovered	and	clinically	used	 to	 treat	patients	with	bacterial	
infections	 and	 related	 diseases	 [1].	 In	 spite	 of	 initial	 success,	
they	 couldn’t	 combat	 the	 emergence	 of	 multiple	 drug	 resis‐
tance	(MDR).	Over	time	microorganisms	develop	resistance	to	
any	 drug,	 making	 them	 less	 effective	 [2‐5].	 Microorganisms	
have	developed	resistance	 to	most	of	 the	current	commercial	
antibiotics	 [6].	 They	 develop	 resistance	 either	 by	 erroneous	
replication,	modifying	 the	 drug	 target	 site	 or	 by	 exchange	 of	
resistant	 traits	 among	 themselves	 [7‐9].	 The	 global	 report	 of	
World	Health	Organization	(WHO)	on	antimicrobial	resistance	
(AMR)	published	in	June,	2014	and	updated	in	2015	mentions	
that	 resistance	of	common	bacteria	 to	 commercial	 antibiotics	
has	 reached	 alarming	 levels	 in	many	parts	 of	 the	world.	 The	
report	 highlights	 that	 resistance	 to	 most	 widely	 used	
antibacterial	 medicines,	 fluoroquinolones	 and	 methicillin	 for	
the	 treatment	 of	 infections	 caused	 by	 E.	 coli	 and	 S.	 aureus,	
respectively,	 is	 very	 widespread	 [10].	 This	 scenario	 poses	 a	
huge	challenge	of	developing	new	classes	of	antibiotics	which	
either	 have	 a	 different	mechanism	 of	 action	 or	 possess	 high	
binding	 affinity	 towards	 the	 target	 site	 of	 resistant	microbial	
strains.	Any	lack	in	development	of	new	antimicrobial	drugs	is	
a	serious	threat	to	public	health	[11].	
Morpholine	moiety	is	of	immense	importance	to	medicinal	
chemists	 and	 has	 been	 used	 as	 core	 scaffold	 and	 capping	
fragment	 to	 design	 new	 drug	 molecules	 [12,13].	 It	 forms	
functional	unit	in	almost	19	FDA	approved	drugs	[14].	One	of	
the	 common	 drugs	 linezolid	 which	 belongs	 to	 the	
oxazolidinone	class	of	antibiotics	contains	morpholine	subunit.	
The	 main	 structural	 feature	 responsible	 for	 its	 popularity	 is	
the	presence	of	oxygen	atom,	which	is	capable	of	participating	
in	 donor‐acceptor	 type	 interactions	 with	 the	 substrate	 and	
thereby	 forms	a	 strong	complex	with	 its	 target.	Oxygen	atom	
also	 complements	 the	 pharmacophoric	 performance	 by	
reducing	 the	 basicity	 of	 nitrogen.	 And	 finally,	 if	 morpholine	
subunit	 gets	 attached	 to	 a	 lipophillic	 scaffold	 it	 increases	 its	
bioavailability	 through	 oral	 administration	 by	 increasing	
aqueous	 solubility	 [15‐18].	 Likewise	 the	 chemistry	 of	
thiazolidine	ring	system	is	of	considerable	interest	as	it	forms	
core	 structure	 of	 many	 biomolecules,	 commercial	 drugs	
[19]and	 synthetic	 molecules	 with	 promising	 antimicrobial,	
antifungal,	 anticancer	 and	 antidiabetic	 activity	 [20‐28].	
Combining	multiple	bioactive	structural	moieties	into	a	single	
molecule	 usually	 complements	 the	 overall	 pharmacophoric	
performance		and		has		been		extensively		used		to		design		new		
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Figure	1.	Reaction	scheme	for	the	synthesis	of	designed	molecules.
	
	
drug	 candidates	 in	 structure	 based	 drug	 design	 [29,30].	
Continuing	 our	 effort	 to	 build	 novel	 biologically	 active	
molecules	 [31,32]	 here,	 we	 designed	 morpholine	 linked	
thiazolidinone	hybrid	molecules	with	the	aim	of	developing	a	
new	 class	 of	 antimicrobials.	 The	molecules	were	 synthesized	
through	a	 three	step	reaction	protocol	which	 involves	simple	
reaction	 setup	 and	 moderate	 reaction	 conditions.	 In	 vitro	
susceptibility	 tests	were	 carried	 against	 some	 selected	 Gram	
positive	 (Staphylococcus	 aureus,	 Bacillus	 subtilis)	 and	 Gram	
negative	 bacteria	 (Escherichia	 coli	 and	 Pseudomonas	
aeruginosa).	 In	 silico	 tools	 are	 continuously	 been	 used	 to	
design	molecules	with	desired	properties.	Molinspiration	and	
Orisis	 programs	 were	 used	 to	 calculate	 some	 crucial	
properties	 for	 the	 designed	 molecules.	 To	 our	 delight,	 the	
designed	 molecules	 gave	 excellent	 results	 for	 all	 such	
properties	 confirming	 the	 potential	 of	 such	 molecules	 as	
possible	drugs.		
When	antibiotics	act	on	particular	bacteria,	they	either	kill	
them	(bactericidal)	or	stop	their	growth	(bacterostatic).	They	
do	so	by	binding	at	cellular	targets	and	inhibiting	their	normal	
function.	 The	 common	 targets	 being	 peptidoglycons	 in	 cell	
wall	 synthesis,	 plasma	 membrane,	 ribosomes	 in	 protein	
synthesis,	 translation,	 transcription,	 DNA/RNA	 replication	
pathway	 and	 metabolites	 of	 cell	 [33,34].	 To	 predict	 the	
possible	target	for	the	designed	molecules,	molecular	docking	
simulations	 were	 done	 against	 nine	 well	 established	 targets	
viz.;	 1BNA,	 1JZQ,	 2RJG,	 2VEG,	 2ZDQ,	 3TTZ,	 3UDI,	 1QG6	 and	
4URM.	 The	 top	 scored	 target	 was	 chosen	 as	 target	 for	 the	
synthesized	molecules.		
	
2.	Experimental	
	
2.1.	Chemistry	
	
Starting	materials,	 reagents	and	 solvents	were	purchased	
either	from	Merck	or	from	Aldrich	and	were	of	reagent	grade.	
Chemicals	 required	 for	 biological	 tests	were	 purchased	 from	
HiMedia.	 Compounds	 were	 synthesized	 mostly	 under	 reflux	
conditions.	 Melting	 points	 were	 determined	 on	 an	 open	
capillary	 apparatus	 and	 are	 reported	 without	 correction.	
Infrared	 spectra	were	 recorded	 on	 a	 Shimadzu	 FT‐IR	DR800	
spectrophotometer	 with	 a	 resolution	 of	 2	 cm‐1	 in	 the	 range	
400‐4000	cm‐1.	1H	NMR	spectra	of	compounds	(in	DMSO‐d6	or	
CDCl3)	 were	 recorded	 on	 Bruker	 AV	 500	 spectrometer	
(Bruker,	Karlsruhe,	Germany)	at	500	MHz.	Peak	multiplicities	
are	 designed	 as:	 s,	 singlet;	 d,	 doublet;	 dd,	 double	 doublet;	 t,	
triplet;	td,	triplet	of	doublets;	m,	multiplet.	Chemical	shifts	(δ)	
are	reported	in	ppm	units	relative	to	TMS	as	internal	standard.	
High‐resolution	mass	spectrometry	was	performed	under	ESI	
conditions	at	a	resolution	of	61800	using	a	Thermo	Scientific	
Exactive	mass	 spectrometer.	 Elemental	 analysis	was	done	by	
Thermo	Scientific	FLASH‐2000	CHN	Analyzer.	The	values	were	
within	 0.4%	 of	 the	 calculated	 values.	 The	 reactions	 were	
monitored	 by	 TLC	 on	 60F254	 silica	 gel	 pre	 coated	 sheets	
(Merck,	Darmstadt,	Germany)	which	were	visualized	under	UV	
(254	and	365	nm)	light,	with	ethyl	acetate:	hexane	(6:4,	v:v)	or	
chloroform:	 methanol	 (9:1,	 v:v)	 as	 solvent	 systems.	 The	
compounds	 were	 purified	 either	 by	 recrystallization	 or	 by	
column	chromatography	with	200‐250	silica	gel	mesh.	
	
2.2.	Design	
	
A	 careful	 survey	 of	 literature	 revealed	 the	 importance	 of	
morpholine	and	 thiazolidinone	moieties	with	 respect	 to	 their	
biological	 potential.	We	 therefore	 designed	 hybrid	molecules	
with	 these	 moieties.	 Structural	 optimization	 of	 the	 final	
product	 with	 electron	 releasing	 (methyl,	 methoxy)	 and	
electron	withdrawing	functionality	(nitro,	halogens)	was	done	
with	 the	 aim	 of	 studying	 electronic	 effects	 on	 activity.	
Halogens,	 particularly	 fluorine	 and	 chlorine	 positively	
influence	 the	 biological	 properties	 of	 molecules.	 Halogen	
bonding	 has	 been	 found	 to	 be	 one	 of	 the	 factors	 by	 which	
chlorine	 alters	 the	 biological	 effect	 of	 molecules	 [35].	
Substitution	 of	 hydrogen	 by	 fluorine	 usually	 has	 a	 positive	
impact	on	the	activity	of	a	molecule	as	fluorine	is	considered	a	
classic	 bioisoster	 for	 hydrogen	 and	 methyl	 groups.	 And	
amongst	 halogens	 bromine	 has	 least	 prevalence	 in	 drugs	 so	
was	 left	out	while	designing	the	molecules	 [36].	Taking	these	
factors	 into	consideration	molecules	were	designed	and	 later	
synthesized	through	a	three	step	reaction	protocol.		
	
2.3.	Synthesis	
	
The	designed	 compounds	were	 synthesized	by	 the	multi‐
step	reaction	protocol	(Figure	1).	The	first	reaction	(formation	
of	 thiourea)	 in	 the	 Figure	 1	 was	 carried	 out	 by	 reacting	 the	
appropriate	 amine	with	phenyl	 isothiocyanate	 in	 chloroform.	
After	 completion	 of	 the	 reaction,	 cyclisation	 of	 this	
intermediate	 was	 achieved	 by	 reacting	 it	 with	 chloroacetyl	
chloride	in	chloroform	and	catalytic	amount	of	NEt3.	The	final	
compounds	 (S2B3‐13)	 in	 the	 series	 were	 obtained	 by	
refluxing	 the	 previous	 intermediates	 with	 commercially	
available	 aromatic	 aldehydes	 in	 presence	 of	 acetic	 acid	 and	
sodium	 acetate	 to	 facilitate	 the	Knoevenagel	 condensation	 at	
the	active	methylene	function	of	thiazolidinone	ring.	
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2.3.1.	General	procedure	for	the	synthesis	of	1‐(2‐morpholi	
noethyl)‐3‐phenylthiourea	(S2B1)		
	
Phenyl	 isothiocyanate	(15	g,	111.11	mmol)	was	dissolved	
in	 chloroform,	 and	 then	4‐(2‐aminoethyl)morpholine	 (8.11	 g,	
111.11	 mmol)	 was	 added	 slowly	 at	 room	 temperature,	 and	
then	refluxed	for	8	hours,	till	white	precipitate	appeared.	The	
precipitate	 was	 collected	 by	 filtration,	 washed	 with	
chloroform,	 and	 dried	 to	 afford	 product	 1	 as	 white	 powder.	
The	 product	 was	 recrystallized	 from	 ethanol	 (95%).	 The	
crystals	 were	 purified	 by	 column	 chromatography	 using	
chloroform:methanol	 (4:1,	 v:v)	 as	 eluent	 to	 afford	 the	
compound	 S2B1	 (Figure	 1).	 Color:	 White.	 Yield:	 90%.	 M.p.:	
250‐254	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3319,	 3261	 (NH,	 thiourea),	
3055	 (CH,	 aromatic).	 1H	 NMR	 (500	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
2.39	 (t,	 4H,	 1,5‐CH2),	 3.37	 (t,	 4H,	 2,4‐CH2),	 3.56	 (t,	 2H,	 CH2),	
3.66	(t,	2H,	CH2),	7.10‐7.40	(m,	5H,	Ar‐H),	7.60	(s,	1H,	NH),	9.70	
(s,	 1H,	 NH).	 13C	 NMR	 (125	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 179.79	
(10CS),	 137.06	 (12C),	 129.93	 (14,16C),	 126.88	 (15C),	 125.21	
(13,17	 C),	 66.87	 (2,4C),	 55.68	 (1,5C),	 52.85	 (7C),	 41.02	 (8C).	
HRMS	(EI,	m/z)	calcd.	for	C13H19N3OS,	265.12;	found	265.25.	
	
2.3.2.	General	procedure	for	the	synthesis	of	(Z)‐3‐(2‐
morpholinoethyl)‐2‐(phenylimino)thiazolidin‐4‐one	(S2B2)	
	
To	 a	 solution	 of	 compound	 S2B1	 in	 chloroform,	
chloroacetyl	 chloride	 was	 added	 drop	 wise	 in	 presence	 of	
catalytic	 amount	 of	 NEt3.	 The	 mixture	 was	 refluxed	 till	 the	
completion	of	reaction	as	monitored	by	TLC	(18h).	The	solvent	
was	evaporated.	Removal	of	the	solvent	gives	an	oily	residue,	
which	 was	 dissolved	 in	 diethyl	 ether	 and	 washed	 with	 an	
aqueous	sodium	carbonate	(10%).	The	organic	layer	was	dried	
over	 sodium	 sulphate,	 filtered,	 and	 concentrated	 (Figure	 1).	
Color:	Light	brown.	Yield:	72%.	M.p.:	285‐287	°C.	FT‐IR	(KBr,	ν,	
cm‐1):	1725	(C=O),	1635	(C=N),	1255	(NCS	ring).	1H	NMR	(500	
MHz,	DMSO‐d6,	δ,	ppm):	2.39	(t,	4H,	N‐CH2‐morpholine),	3.37	
(t,	4H,	O‐CH2‐morpholine),	3.42	(t,	2H,	CH2),	3.56	(t,	2H,	CH2),	
3.90	(2H,	CH,	thiazolidinone	ring),	7.10‐7.40	(m,	5H,	Ar‐H).	13C	
NMR	 (125	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 169.95	 (10CO),	 31.35	
(11C),	 152.52	 (13C),	 129.93	 (17,19C),	 126.88	 (18C),	 125.21	
(16,20	 C),	 66.87	 (2,4C),	 55.68	 (1,5C),	 50.15	 (7C),	 44.12	 (8C).	
HRMS	(EI,	m/z)	calcd.	for	C15H19N3O2S,	305.12;	found	305.36.	
	
2.3.3.	General	procedure	for	the	synthesis	of	(2Z,5E)‐5‐
(substituted	benzylidene)‐3‐(2‐morpholinoethyl)‐2‐(pheny	
limino)thiazolidin‐4‐one	(S2B3‐13)	
	
To	 a	 solution	 of	 compound	 S2B2	 (35	 mmol)	 in	 acetic	
acid/sodium	acetate	 buffer	 (50	mL),	 aromatic	 aldehydes	 (1.5	
equiv.)	 were	 added	 in	 subsequent	 reactions	 to	 get	 the	 final	
products.	 The	 solution	 was	 refluxed	 till	 the	 completion	 of	
reaction	 as	 monitored	 by	 TLC.	 The	 reaction	 mixture	 was	
allowed	 to	 cool	 at	 room	 temperature,	 filtered	 and	
recrystallized	from	ethanol	(Figure	1).		
(2Z,	 5E)‐5‐benzylidene‐3‐(2‐morpholinoethyl)‐2‐(phenyl	
imino)thiazolidin‐4‐one	 (S2B3):	 Color:	 Brown.	 Yield:	 75%.	
M.p.:	390‐395	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1710	(C=O),	1639	(C=N),	
1250	(NCS	ring).	1H	NMR	(500	MHz,	DMSO‐d6,	δ,	ppm):	2.39	(t,	
4H,	N‐CH2‐morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	
(t,	 4H,	 O‐CH2‐morpholine),	 3.56	 (t,	 2H,	 CH2‐N‐thiazolidinne),	
6.90‐7.40	(m,	11H,	Ar‐H	+	CH‐arylidene).	13C	NMR	(125	MHz,	
DMSO‐d6,	δ,	ppm):	167.35	(10CO),	117.21	(11C),	152.52	(13C),	
129.93	(17,19C),	126.88	(18C),	125.21	(16,20	C),	66.87	(2,4	C),	
55.68	(1,5	C),	52.85	(7C),	41.5	(8C),	142.25	(21C),	134.5	(22C),	
128.5	(23,27C),	128.05	(24,26	C),	127.5	(25	C).	HRMS	(EI,	m/z)	
calcd.	for	C22H23N3O2S,	393.15;	found	393.45.	
(2Z,	 5E)‐5‐(3‐fluorobenzylidene)‐3‐(2‐morpholinoethyl)‐2‐
(phenylimino)thiazolidin‐4‐one	(S2B4):	Color:	Brown.	Yield:	70	
%.	M.p.:	365‐370	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1715	(C=O),	1070	(C‐
F).	 1H	NMR	 (500	MHz,	DMSO‐d6,	 δ,	 ppm):	2.39	 (t,	 4H,	N‐CH2‐
morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	 (t,	 4H,	 O‐
CH2‐morpholine),	 3.56	 (t,	 2H,	 CH2‐N‐thiazolidinne),	 6.80	 (d,	
1H,	Ar‐H),	7.01	(dd,	1H,	J	=	7.5	Hz,	3Hz,	Ar‐H),	7.09	(d,	1H,	Ar‐
H),	7.10‐7.40	(m,	7H,	Ar‐H	+	CH‐arylidene).	13C	NMR	(125	MHz,	
DMSO‐d6,	δ,	ppm):	167.35	(10CO),	117.21	(11C),	152.52	(13C),	
129.93	 (17,19	 C),	 126.88	 (18C),	 125.21	 (16,20	 C),	 66.87	 (2,4	
C),	55.68	 (1,5	C),	52.85	 (7C),	41.5	 (8C),	135.01	 (21C),	117.05	
(11C),	170.02	(10C),	150.3	(13C),	44.5	(8C),	134.5	(22C),	115.4	
(23C),	 164.5	 (24C),	 109.3	 (25C),	 125.5	 (26C),	 123.5	 (27C).	
HRMS	(EI,	m/z)	calcd.	for	C22H22FN3O2S,	411.14;	found	411.18.	
(2Z,	5E)‐5‐(3‐chlorobenzylidene)‐3‐(2‐morpholinoethyl)‐2‐
(phenylimino)thiazolidin‐4‐one	 (S2B5):	 Color:	 Light	 brown.	
Yield:	70%.	M.p.:	370‐372	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1045	(C‐Cl).	
1H	 NMR	 (500	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 2.39	 (t,	 4H,	 N‐CH2‐
morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	 (t,	 4H,	 O‐
CH2‐morpholine),	3.56	(t,	2H,	CH2‐N‐thiazolidinne),	7.05	(s,	1H,	
CH‐arylidene),	7.10‐7.40	 (m,	8H,	Ar‐H),7.53	 (d,	1H,	Ar‐H).	 13C	
NMR	 (125	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 167.35	 (10CO),	 117.21	
(11C),	 152.52	 (13C),	 129.93	 (17,19	 C),	 126.88	 (18C),	 125.21	
(16,20	C),	 66.87	 (2,4	C),	 55.68	 (1,5	C),	 52.85	 (7C),	 41.5	 (8C),	
135.01	 (21C),	 117.05	 (11C),	 170.02	 (10C),	 150.3	 (13C),	 44.5	
(8C),	 134.6	 (22C),	 121.5	 (23C),	 133.5	 (24C),	 120.3	 (25C),	
126.01	 (26C),	 125.5	 (27C).	 HRMS	 (EI,	 m/z)	 calcd.	 for	
C22H22ClN3O2S,	427.11;	found	427.17.	
(2Z,	 5E)‐5‐(3‐methylbenzylidene)‐3‐(2‐morpholinoethyl)‐
2‐(phenylimino)thiazolidin‐4‐one	 (S2B6):	 Color:	 Brown.	 Yield:	
62%.	 M.p.:	 362‐365	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 2955	 (C‐H).	 1H	
NMR	 (500	MHz,	DMSO‐d6,	 δ,	 ppm):	2.31	 (s,	 3H,	 CH3),	 2.39	 (t,	
4H,	N‐CH2‐morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	
(t,	 4H,	 O‐CH2‐morpholine),	 3.56	 (t,	 2H,	 CH2‐N‐thiazolidinne),	
7.00	 (s,	1H,	CH‐	arylidene),	7.10‐7.41	(m,	9H,	Ar‐H).	 13C	NMR	
(125	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 167.35	 (10CO),	 117.21	 (11C),	
152.52	 (13C),	 129.93	 (17,19	 C),	 126.88	 (18C),	 125.21	 (16,20	
C),	 66.87	 (2,4	 C),	 55.68	 (1,5C),	 52.85	 (7C),	 41.5	 (8C),	 135.01	
(21C),	 117.05	 (11C),	 170.02	 (10C),	 150.3	 (13C),	 44.5	 (8C),	
134.5	 (22C),	 124.5	 (23C),	 136.5	 (24C),	 121.2	 (25C),	 124.3	
(26C),	 124.9	 (27C).	 HRMS	 (EI,	 m/z)	 calcd.	 for	 C23H25N3O2S,	
407.17;	found	407.20.	
(2Z,	 5E)‐3‐(2‐morpholinoethyl)‐5‐(3‐nitrobenzylidene)‐
2‐(phenylimino)thiazolidin‐4‐one	 (S2B7):	 Color:	 Yellow.	 Yield:	
75	%.	M.p.:	 415‐420	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1525	 (N=O).	 1H	
NMR	 (500	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 2.39	 (t,	 4H,	 N‐CH2‐
morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	 (t,	 4H,	 O‐
CH2‐morpho	line),	3.56	(t,	2H,	CH2‐N‐thiazolidinne),	7.11‐7.41	
(m,	6H,	Ar‐H	+	CH‐arylidene),	7.63	(td,	1H,	Ar‐H),	7.68	(dd,	1H,	
Ar‐H),	 8.15	 (d,	 1H,	 Ar‐H),	 8.32	 (d,	 1H,	 Ar‐H).	 13C	 NMR	 (125	
MHz,	DMSO‐d6,	δ,	ppm):	167.35	(10CO),	117.21	(11C),	152.52	
(13C),	129.93	(17,19	C),	126.88	(18C),	125.21(16,20	C),	66.87	
(2,4	 C),	 55.68	 (1,5	 C),	 52.85	 (7C),	 41.5	 (8C),	 135.01	 (21C),	
117.05	 (11C),	 170.02	 (10C),	 150.3	 (13C),	 44.5	 (8C),	 134.5	
(22C),	 119.5	 (23C),	 146.5	 (24C),	 120.01	 (25C),	 125.5	 (26C),	
134.5	 (27C).	 HRMS	 (EI,	m/z)	 calcd.	 for	 C22H22N4O4S,	 438.14;	
found	438.35.	
(2Z,	5E)‐5‐(3‐methoxybenzylidene)‐3‐(2‐morpholinoethyl)‐
2‐(phenylimino)thiazolidin‐4‐one	 (S2B8):	 Color:	 Dark	 brown.	
Yield:	65	%.	M.p.:	375‐380	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1170	(C‐O).		
1H	NMR	(500	MHz,	DMSO‐d6,	δ,	ppm):	1.25	(s,	3H,	OCH3),	2.39	
(t,	 4H,	 N‐CH2‐morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	
3.37	 (t,	 4H,	 O‐CH2‐morpholine),	 3.56	 (t,	 2H,	 CH2‐N‐thiazoli	
dine),	7.05	(s,	1H,	CH‐arylidene),	7.10‐7.41	(m,	8H,	Ar‐H),	7.53	
(d,	 1H,	 Ar‐H).	 13C	NMR	 (125	MHz,	DMSO‐d6,	 δ,	 ppm):	 167.35	
(10CO),	117.21	(11C),	152.52	(13C),	129.93	(17,19	C),	126.88	
(18C),	 125.21	 (16,20	 C),	 66.87	 (2,4	 C),	 55.68	 (1,5	 C),	 52.85	
(7C),	 41.5	 (8C),	 135.01	 (21C),	 117.05	 (11C),	 170.02	 (10C),	
150.3	(13C),	44.5	(8C),	134.5	(22C),	115.5	(23C),	162.2	(24C),	
115.4	 (25C),	125.4	 (26C),	119.5	 (27C).	HRMS	(EI,	m/z)	calcd.	
for	C23H25N3O3S,	423.16;	found	423.19.	
(2Z,	 5E)‐5‐(4‐fluorobenzylidene)‐3‐(2‐morpholinoethyl)‐2‐
(phenylimino)thiazolidin‐4‐one	(S2B9):	Color:	Brown.	Yield:	65	
%.	M.p.:	385‐390	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1155	(C‐F).	1H	NMR	
(500	MHz,	DMSO‐d6,	δ,	ppm):	2.39	(t,	4H,	N‐CH2‐morpholine),	
3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	 (t,	 4H,	 O‐CH2‐morpho	
line),	3.56	(t,	2H,	CH2‐N‐thiazolidinne),	7.11‐7.39	(m,	8H,	Ar‐H	
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+	 CH‐arylidene),	 7.55	 (dd,	 2H,	 Ar‐H).	 13C	 NMR	 (125	 MHz,	
DMSO‐d6,	δ,	ppm):	167.35	(10CO),	117.21	(11C),	152.52	(13C),	
129.93	 (17,19	 C),	 126.88	 (18C),	 125.21	 (16,20	 C),	 66.87	 (2,4	
C),	 55.68	 (1,5C),	 52.85	 (7C),	 41.5	 (8C),	 134.04	 (21C),	 116.07	
(11C),	170.02	(10C),	150.3	(13C),	44.5	(8C),	131.5	(22C),	130.2	
(23,27	C),	117.5	(24,26	C),	165.05	(25C).	HRMS	(EI,	m/z)	calcd.	
for	C22H22FN3O2S,	411.14;	found	411.17.		
(2Z,	5E)‐5‐(4‐chlorobenzylidene)‐3‐(2‐morpholinoethyl)‐2‐
(phenylimino)thiazolidin‐4‐one	 (S2B10):	 Color:	 Light	 brown.	
Yield:	 72%.	 M.p.:	 395‐400	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1025	 (C‐
Cl).1H	 NMR	 (500	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 2.39	 (t,	 4H,	 CH2‐
morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	 (t,	 4H,	 O‐
CH2‐morpholine),	 3.56	 (t,	 2H,	 CH2‐N‐thiazolidinne),	 7.10‐7.42	
(m,	10H,	Ar‐H	+	CH‐arylidene).	13C	NMR	(125	MHz,	DMSO‐d6,	δ,	
ppm):	 167.35	 (10CO),	 117.21	 (11C),	 152.52	 (13C),	 129.93	
(17,19	C),	126.88	(18C),	125.21	(16,20		C),	66.87	(2,4	C),	55.68	
(1,5	 C),	 52.85	 (7C),	 41.5	 (8C),	 134.04	 (21C),	 116.07	 (11C),	
170.02	 (10C),	 150.3	 (13C),	 44.5	 (8C),	 132.5	 (22C),	 128.7	
(23,27	C),	129.5	(24,26	C),	135.02	(25C).	HRMS	(EI,	m/z)	calcd.	
for	C22H22ClN3O2S,	427.11;	found	427.36.	
(2Z,	 5E)‐5‐(4‐methylbenzylidene)‐3‐(2‐morpholinoethyl)‐2‐
(phenylimino)thiazolidin‐4‐one	 (S2B11):	 Color:	 Brown.	 Yield:	
62	%.	M.p.:	 374‐378	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 2955	 (C‐H).	 1H	
NMR	 (500	MHz,	DMSO‐d6,	 δ,	 ppm):	2.43	 (s,	 3H,	CH3),	 2.39	 (t,	
4H,	N‐CH2‐morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	
(t,	 4H,	 O‐CH2‐morpholine),	 3.56	 (t,	 2H,	 CH2‐N‐thiazolidinne),	
7.11‐7.41	(m,	8H,	Ar‐H	+	CH‐arylidene),	7.52	(d,	2H,	Ar‐H).	13C	
NMR	 (125	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 167.35	 (10CO),	 117.21	
(11C),	 152.52	 (13C),	 129.93	 (17,19	 C),	 126.88	 (18C),	 125.21	
(16,20	C),	 66.87	 (2,4	C),	 55.68	 (1,5	C),	 52.85	 (7C),	 41.5	 (8C),	
134.04	 (21C),	 116.07	 (11C),	 170.02	 (10C),	 150.3	 (13C),	 44.5	
(8C),	 131.2	 (22C),	 127.3	 (23,27	 C),	 129.2	 (24,26	 C),	 139.5	
(25C).	 HRMS	 (EI,	m/z)	 calcd.	 for	 C23H25N3O2S,	 407.17;	 found	
407.28.	
(2Z,	5E)‐3‐(2‐morpholinoethyl)‐5‐(4‐nitrobenzylidene)‐2‐
(phenylimino)thiazolidin‐4‐one	 (S2B12):	 Color:	 Yellow.	 Yield:	
80	%.	M.p.:	405‐410	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1515	(C‐NO2).	1H	
NMR	(500	MHz,	DMSO‐d6,	δ,	ppm):	2.39	(t,	4H,	N‐CH2‐morpho	
line),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	 (t,	 4H,	 O‐CH2‐
morpholine),	 3.56	 (t,	 2H,	 CH2‐N‐thiazolidinne),	 7.10‐7.41	 (m,	
6H,	Ar‐H	+	CH‐	arylidene),	7.69	(dd,	2H,	Ar‐H),	8.22	(d,	2H,	Ar‐
H).	 13C	 NMR	 (125	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 167.35	 (10CO),	
117.21	 (11C),	 152.52	 (13C),	 129.93	 (17,19	 C),	 126.88	 (18C),	
125.21	(16,20	C),	66.87	(2,4	C),	55.68	(1,5	C),	52.85	(7C),	41.5	
(8C),	 134.04	 (21C),	 116.07	 (11C),	 170.02	 (10C),	 150.3	 (13C),	
44.5	(8C),	140.5	(22C),	129.2	(23,27	C),	126.5	(24,26	C),	147.5	
(25C).	 HRMS	 (EI,	m/z)	 calcd.	 for	 C22H22N4O4S,	 438.14;	 found	
438.35.	
(2Z,	5E)‐5‐(4‐methoxybenzylidene)‐3‐(2‐morpholinoethyl)‐
2‐(phenylimino)thiazolidin‐4‐one	 (S2B13):	Color:	Dark	brown.	
Yield:	62	%.	M.p.:	410‐414	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1165	(C‐O).		
1H	 NMR	 (500	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 2.39	 (t,	 4H,	 N‐CH2‐
morpholine),	 3.12	 (t,	 2H,	 CH2‐N‐Morpholine),	 3.37	 (t,	 4H,	 O‐
CH2‐morpholine),	3.56	(t,	2H,	CH2‐N‐thiazolidinne),	3.78	(s,	3H,	
OCH3),	 7.00	 (d,	 2H,	 Ar‐H),	 7.12‐7.41	 (m,	 6H,	 Ar‐H	 +	 CH‐
arylidene),	7.50	(dd,	2H,	Ar‐H).	 13C	NMR	(125	MHz,	DMSO‐d6,	
δ,	 ppm):	 167.35	 (10CO),	 117.21	 (11C),	 152.52	 (13C),	 129.93	
(17,19	C),	126.88	(18C),	125.21	(16,20	C),	66.87	(2,4	C),	55.68	
(1,5	 C),	 52.85	 (7C),	 41.5	 (8C),	 134.04	 (21C),	 116.07	 (11C),	
170.02	(10C),	150.3	(13C),	44.5	(8C),	126.3	(22C),	128.5	(27C),	
112.16	 (26C),	 162.5	 (25C).	 HRMS	 (EI,	 m/z)	 calcd.	 for	
C23H25N3O3S,	423.16;	found	423.19.	
	
2.4.	Antimicrobial	activity	
	
Disk	 diffusion	 susceptibility	 method	 [37]	 in	 accordance	
with	 National	 Committee	 for	 Clinical	 Laboratory	 Standards	
(NCCLS)	 guidelines	 was	 used	 for	 initial	 screening	 of	 com‐
pounds	 for	 antibacterial	 activity	 against	 Gram	 positive	 (B.	
subtilis	 (MTCC10619)	 and	 S.	 aureus	 (MTCC	 96))	 and	 Gram	
negative	 bacteria	 (P.	 aeruginosa	 (MTCC1748)	 and	 E.	 coli	
(MTCC	68)).	Pure	microbial	strains	were	obtained	from	MTCC	
IMTECH,	 Chandigarh,	 India.	 Müeller‐Hinton	 agar	 (HiMedia)	
was	melted	and	subsequently	poured	(20	mL)	into	Petri	plates	
(100mm)	 and	 kept	 undisturbed	 at	 room	 temperature	 to	
solidify.	A	representative	sample	of	the	media	was	kept	at	37	
°C	 in	 BOD	 incubator	 for	 24	 hours	 to	 check	 the	 sterility.	 The	
culture	of	each	bacterium	in	saline	was	uniformly	spread	over	
the	media	with	a	cotton	swab.	Sterile	filter	paper	discs	of	6	mm	
diameter	 (HiMedia)	 impregnated	 with	 particular	 concent‐
ration	of	compounds	(in	DMSO)	was	applied	to	the	surface	of	
inoculated	plates.	The	plates	were	kept	 in	BOD	 incubator	 for	
24	 hr	 at	 37	 °C	 and	 subsequently	 examined	 for	 bacterial	
growth.	 The	 results	 are	 expressed	 aszone	 of	 inhibition	 in	
millimeters	(mm).	Experiments	were	done	in	triplicate	and	on	
average	standard	deviation	of	<	2	were	observed.	
Agar	 dilution	method	 [38]	was	used	 to	 calculate	 the	MIC	
(minimum	 inhibitory	 concentration)	 of	 synthesized	 com‐
pounds.	 The	 pure	 bacterial	 strains	 were	 streaked	 onto	
nutrient	 rich	 (Mueller	 Hinton)	 agar	 plates	 to	 obtain	 single	
colonies.	The	plates	were	incubated	at	37	°C	for	22	hours.	For	
each	 strain,	 four	 morphologically	 similar	 colonies	 were	
selected	 and	 transferred	 with	 a	 cotton	 swab	 into	 sterile	
capped	glass	tube	containing	sterile	saline	solution.	 Inoculum	
size	for	each	test	strain	was	adjusted	to	104	CFU/mL	(Colony	
Forming	 Unit	 per	 milliliter)	 with	 sterile	 saline	 through	
turbidimetric	method.	Stock	solution	of	1000	μg/mL	for	each	
compound	 was	 prepared	 in	 1%	 DMSO.	 The	 stock	 solutions	
were	 further	 diluted	 with	 saline	 to	 get	 solutions	 of	
concentrations	500	to	2.4	μg/mL.	1mL	each	of	the	test	solution	
and	 bacterial	 inoculum	 (104	 CFU/mL)	 was	 mixed	 with	
nutrient	 agar	 and	 poured	 in	 petriplates.	 The	 plates	 were	
incubated	at	37	°C	for	24	hrs.	MICs	were	defined	as	the	lowest	
concentration	of	tested	compound	which	prevented	the	visible	
growth	of	bacteria.	
	
2.5.	Molecular	docking	
	
Molecular	 docking	 calculations	 were	 performed	 on	
Autodock	 VINA	 software	 [39].	 High	 resolution	 crystal	
structure	 of	 nine	 targets	 were	 downloaded	 from	 RCSB	 PDB	
website.	 The	 protein	was	 prepared	 for	 docking	 by	 removing	
waters,	 co‐factors	 (except	 NADH)	 and	 co‐crystallized	 ligands	
using	 Discovery	 Studio	 Visualizer	 (DSV)	 4.0.	 NADH	 was	
retained	as	 the	antimicrobial	drugs	acts	complex	with	NADH.	
Atomic	 charges	were	calculated	using	Kollman	method,	polar	
hydrogens	were	added	and	finally	grid	dimensions	(40×40×40	
Å)	were	defined	so	as	to	 include	all	 the	residues	of	the	active	
site	 in	 Auto	 dock	 tools	 (ADT).	 For	 docking,	 the	 ligands	were	
prepared	 by	 converting	 the	 2D	 to	 3D	 geometry	 followed	 by	
optimization	 at	 semi‐empirical	 (PM3)	 level	 of	 theory.	 Atomic	
charges	were	 calculated	 by	Geistenger	method.	 Torsions	 and	
rotatable	bonds	were	defined	 in	ADT.	To	 test	 the	accuracy	of	
the	 docking	 protocol,	 the	 co‐crystallized	molecule	 (triclosan)	
was	 removed	 from	 the	 protein	 structure	 and	was	 docked	 at	
the	active	site	(to	remove	any	crystallographic	bias	the	ligand	
was	drawn	and	optimized	de	novo).	The	docking	protocol	we	
employed	 predicted	 the	 same	 conformation	 as	 that	 in	 the	
crystal	structure	with	RMSD	values	well	within	1	Å	(Figure	2).	
Autodock	 VINA	 predicts	 bound	 conformations	 and	 calculates	
the	 binding	 affinity.	 Both	 the	 parameters	 have	 significance	
while	carrying	virtual	screening.	Out	of	the	nine	conformations	
predicted	 by	 Autodock	 VINA	 for	 each	 molecule,	 the	 confor‐
mation	which	was	 close	 to	 co‐crystallized	 ligand	 and	 scored	
well	 was	 chosen	 as	 the	 active	 conformation.	 These	 confor‐
mations	 were	 visualized	 in	 DSV	 (Accelrys	 Software	 Inc.)	 and	
LigandPlus	 [40]	 software	 to	 get	 insights	 into	 the	 interactions	
involved.		
	
3.	Results	and	discussions	
	
3.1.	Spectral	analysis	
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Figure	 2.	 Superimposition	 of	 docked	 conformation	 (yellow)	 over	 the	 co‐crystallized	 conformation(blue)	 of	 triclosan	 shows	 RMSD	 value	 close	 to	 zero,	
confirming	the	reliability	of	docking	protocol.	H‐bonding	surface	and	active	site	residues	are	shown	for	clarity.	
	
	
	
	
Figure	3.	(a)	Structure	of	S2B3	with	atom	numbering	for	NMR	interpretation,	(b)	DFT‐B3LYP/6‐31G(d,p)	optimized	geometry	of	S2B3.
	
	
The	 formation	 of	 compound	 S2B1	 (Figure	 1)	 was	
confirmed	by	recording	its	FT‐IR,	1H	NMR,	13C	NMR	and	HRMS	
spectra.	 Presence	 of	 N‐H	 stretching	 vibrations	 at	 3319	 and	
3261	 cm‐1	 confirms	 the	 formation	 of	 thiourea.	 Shifts	 in	
aromatic	 C‐H	 stretch	 (3055	 cm‐1)	 and	 disappearance	 of	
primary	 amine	 vibrations	 corroborated	 the	 above	 results.	
1HNMR	spectra	of	compound	S2B1	showed	two	broad	singlets	
which	were	interpreted	for	thiourea	N‐H	at	δ	7.6	and	9.7	ppm.	
The	most	prominent	peaks	 in	 13C	NMR	spectra	at	δ	179	ppm	
confirmed	the	presence	of	C=S	linkage.	The	molecular	ion	peak	
([M]+	 =	 265.25	m/z)	 corresponded	 to	 the	molecular	mass	 of	
the	compound.		
The	formation	of	compound	S2B2	was	similarly	confirmed	
from	 the	 corresponding	 spectra.	 FT‐IR	 spectra	 show	 a	 sharp	
band	 at	 1725	 cm‐1,	 which	 was	 assigned	 for	 carbonyl	 C=O	
stretch.	 Disappearance	 of	 N‐H	 and	 C=S	 stretching	 vibrations	
and	 presence	 of	 N=C	 and	 ring	 N‐C‐S	 vibrations	 at	 1635	 and	
1255	 cm‐1	 confirm	 the	 formation	 of	 thiazolidinone	 ring.	 13C	
NMR	spectra	shows	peaks	for	carbonyl	and	methylene	carbons	
at	 δ	 169	 and	 31	 ppm,	 respectively,	 which	 is	 consistent	 with	
formation	of	thiazolidinone	ring.	The	molecular	ion	peak	([M]+	
=	 305.36	 m/z)	 corresponds	 to	 the	 molecular	 mass	 of	 the	
compound.	
The	 final	 compounds	 S2B3‐13	 were	 similarly	 charac‐
terized	by	recording	the	FT‐IR,	1H	NMR	and	13C	NMR	spectra	of	
the	 compounds.	 The	 absorption	 band	 at	 1515	 cm‐1	 in	 FT‐IR	
spectra	 corresponds	 to	 arylidene	 C=C	 stretch.	 A	 singlet	 at	 δ	
6.9‐7.2	ppm	and	a	multiplet	at	δ	6.9‐8.1	ppm	corresponding	to	
CH	 and	 aromatic	 protons,	 respectively,	 confirmed	 the	
formation	 of	 the	 subsequent	 compounds.	 The	 substitution	
pattern	 in	 the	 phenyl	 ring	 was	 confirmed	 from	 the	 splitting	
pattern	and	corresponding	coupling	constants	in	the	aromatic	
region	of	NMR	spectra.	A	representative	figure	for	S2B3	with	
numbering	for	NMR	interpretation	is	shown	in	Figure	3.		
	
3.2.	In	silico	study	of	drug	likeness	and	molecular	
properties	
	
As	 a	 starting	 point	 to	 evaluate	 the	 pharmaceutical	
potential	of	the	synthesized	molecules,	we	decided	to	calculate	
some	 in	 silico	 properties	 for	 these	 molecules.	 Most	 of	 the	
clinical	 drugs	 available	 in	 market	 possess	 some	 peculiar	
properties	 and	 it	 has	 been	 possible	 to	 quantitatively	
differentiate	 such	 properties	 (descriptors).	 A	 drug	 candidate	
should	 have	 certain	 structural	 features	 which	 increase	 its	
bioavailability	and	help	it	cross	the	blood	brain	barrier.	It	has	
become	possible	to	quantify	such	structural	features	in	terms	
of	 molecular	 properties	 like	 "Rule	 of	 five",	 Molecular	 Polar	
Surface	Area	(TPSA),	Molecular	Volume,	Number	of	Rotatable	
Bonds	 (nrotb)	 etc.	 The	 Lipinski	 “Rule	 of	 five”	 [41]	 highlights	
the	importance	of	physical	parameters	like	lipophilicity	(log	P	
≤	 5),	molecular	weight	 (≤	 500)	 and	 the	 number	 of	 hydrogen	
bond	 donors	 (≤	 10)/acceptors	 (≤	 10)	 for	 bioavailability	 and	
oral	 absorption.	 TPSA	 descriptor	 characterizes	 drug	
absorption,	 intestinal	 absorption,	 bioavailability,	 Caco‐2	
permeability	and	blood‐brain	barrier	penetration	[42].	
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Table	1.	Orisis	prediction	of	molecular	volume,	molecular	total	polar	surface	area	(TPSA),	drug	score,	number	of	rotatable	bonds	(nrotb)	and	solubility	(log	S).	
Compound	 Volume	 Total	polar	surface	area	(TPSA) Drug	score Number	of	rotatable	bonds	(nrotb)	 log	S,	log	(moles/L)
S2B3	 356.92	 46.84	 0.34	 5	 ‐4.57	
S2B4	 361.85	 46.84	 0.43 5 ‐4.88	
S2B5	 370.46	 46.84	 0.50	 5	 ‐5.46	
S2B6	 373.48	 46.84	 0.39	 5	 ‐4.89	
S2B7	 380.25	 92.67	 ‐0.06	 6	 ‐5.34	
S2B8	 382.47	 56.08	 0.46 6 ‐4.71	
S2B9	 361.85	 46.84	 0.68 5 ‐5.09	
S2B10	 370.46	 46.84	 0.83 5 ‐5.53	
S2B11	 373.48	 46.84	 0.37 5 ‐5.03	
S2B12	 380.25	 92.67	 ‐0.11 6 ‐5.42	
S2B13	 382.47	 56.08	 0.50 6 ‐4.83	
	
	
Table	2.	 Prediction	 of	 Lipinski	 parameters;	mi	Log	P	 (Molinspiration	 Partitian	 Function),	 natoms	 (total	 no	 of	 atoms),	MW	(molecular	weight),	 nON	 (no	 of	
hydrogen	bond	acceptors),	nOHNH	(no	of	hydrogen	bond	donors).	
Compound	 mi	Log	P	 natoms	 MW	 nON	 nOHNH	 nviolations	
S2B3	 3.71	 28	 393.51 5 0 0	
S2B4	 3.98	 23.0 411.50 5 0 0	
S2B5	 4.42	 23.0 427.96 5 0 0	
S2B6	 4.11	 23.0 407.54 5 0 0	
S2B7	 3.38	 25.0	 438.51	 8	 0	 0	
S2B8	 3.80	 24.0	 423.54	 6	 0	 0	
S2B9	 3.98	 23.0	 411.50	 5	 0	 0	
S2B10	 4.42	 23.0 427.96 5 0 0	
S2B11	 4.11	 23.0	 407.54	 5	 0	 0	
S2B12	 3.38	 25.0 438.51 8 0 0	
S2B13	 3.80	 24.0 423.54 6 0 0	
	
	
Table	3.	MIC	values	in	µg/mL±SD	(n	=	3)	for	the	synthesized	molecules	calculated	by	agar	dilution	method	(The	experiments	were	done	in	triplicate).		
Compound	 Minimum	inhibitory	concentration	(MIC)	against	bacteria	in	µg/mL	±SD
S.	aureus	(MTCC	96)	 B.	subtilis	(MTCC	10619)	 E.	coli	(MTCC	68)	 P.	aeruginosa	(MTCC	1748)	
S2B3	 12.5±0.2	 12.5±0.6 25±0.62 50±0.62	
S2B4	 12.5±0.1	 6.25±0.9 3.125±0.60 12.5±0.2	
S2B5	 6.25±0.62	 12.5±0.2	 25±0.62	 3.125±0.60	
S2B6	 25±0.62	 50±0.62	 12.5±0.2	 200±0.62	
S2B7	 3.125±0.25	 12.5±0.30	 2.0±0.12	 12.5±0.2	
S2B8	 6.25±0.62	 12.5±0.0	 50±0.62	 25±1.62	
S2B9	 12.5±0.5	 25±0.60 25±0.62 100±0.62	
S2B10	 6.25±0.62	 25±0.62 50±0.62 12.5±0.6	
S2B11	 12.5±0.20	 50±0.60 6.125±0.60 25±0.62	
S2B12	 12.5±0.5	 50±0.30 12.5±0.2 6.25±0.60	
S2B13	 25±0.5	 12.5±0.2 6.25±0.62 12.5±0.2	
Ciprofloxacin	 3.125±0.82	 6.25±0.24 3.125±0.4 3.125±0.42	
Streptomycin	 6.25±0.62	 3.125±0.2	 6.25±0.6	 3.125±0.42	
	
	
Nrotb	 topological	 parameter	 is	 a	 measure	 of	 molecular	
flexibility	and	is	a	good	descriptor	for	oral	bioavailability	[43].	
Molecular	 properties	 for	 the	 synthesized	 compounds	 were	
calculated	by	Molinspiration	and	Orisis	web	servers	are	shown	
in	Table	1	[44].	
None	 of	 the	 synthesized	 molecules	 violates	 the	 Lipinski	
Rule	 of	 five.	 Among	 the	 synthesized	 compounds	 Orisis	
property	 explorer	 predicts	 the	 floro,	 chloro	 and	 methoxy	
derivatives	 to	 be	 better	 drug	 candidates	 in	 terms	 of	 oral	
absorption	 and	 overall	 bioavailability	 as	 compared	 to	 others	
however	 on	 an	 overall	 basis	 all	 the	 synthesized	 molecules	
score	 pretty	 well	 for	 all	 the	 calculated	 properties	 (Table	 2).	
Halogens	 particularly	 fluorine	 and	 chlorine	 positively	
influence	 the	 biological	 properties	 of	 molecules.	 Halogen	
bonding	 has	 been	 found	 to	 be	 one	 of	 the	 factors	 by	 which	
chlorine	 alters	 the	 biological	 effect	 of	 molecules.	 The	
molinspiration	 predicts	 that	 the	 nitro	 derivatives	 because	 of	
large	polar	surface	area	 show	better	 interaction	compared	 to	
other	 derivatives.	 From	 these	 studies	 it	 was	 found	 that	 the	
molecules	possess	drug	 like	properties	 and	 can	 interact	with	
biomolecules	 to	 exert	 a	 particular	 effect.	 Having	 satisfied	
ourselves	 with	 primary	 in	 silico	 screening	 assay	 of	 these	
compounds	we	decided	to	carry	in	vitro	antimicrobial	activity	
of	 these	 compounds	 to	 further	 investigate	 their	 biological	
potential.	
	
3.3.	Antimicrobial	activity	
	
As	is	evident	from	Table	3,	compound	S2B7	was	found	to	
be	 the	most	 active	molecule	 in	 terms	 of	MIC.	MIC	 value	 of	 2	
µg/mL	 was	 found	 against	 E.	 coli.	 A	 look	 at	 the	 structure	 of	
S2B7	shows	that	the	structural	feature	responsible	for	its	high	
activity	 is	 the	 presence	 of	 nitro	 group	 at	 the	meta	 position	
wherein	nitrogen	and	oxygen	atoms	provide	polar	surfaces	for	
interaction	with	substrate	molecules.	A	careful	observation	of	
MIC	values	shows	that	methyl	substitution	suppresses	activity	
and	 presence	 of	 NO2	 and	 Cl	 groups	 enhance	 activity.	 As	 is	
evident	 from	 Table	 3,	 most	 of	 the	 compounds	 inhibit	 the	
growth	 of	 both	 gram	 positive	 as	 well	 as	 Gram	 negative	
bacterial	 strains	 to	 substantial	 levels.	 Examining	 the	 MIC	
values	 (Table	 3)	 shows	 S2B7	 to	 be	 most	 potent	 molecule	
against	P.	aeruginosa	with	MIC	value	2.5	µg/mL	which	is	better	
than	the	standard	drugs	Streptomycin	and	Ciprofloxacin	with	
MIC	value	3.125	µg/mL,	 this	 is	 followed	by	S2B4	 and	S2B11	
with	MIC	value	3.125	and	6.25	µg/mL,	 respectively.	The	high	
activity	of	S2B5	and	S2B12	against	P.	aeruginosa	is	attributed	
to	the	presence	of	Cl	and	NO2	groups	which	both	complement	
the	 activity.	 As	 reveled	 by	 docking	 these	 groups	 help	 the	
molecule	to	attain	a	conformation	which	fits	the	target	site	and	
binds	 through	 multiple	 interactions.	 For	 most	 of	 the	
compounds	 the	 docking	 scores	 how	 a	 good	 correlation	 with	
the	MICs	 for	 compounds	 against	E.	 coli.	The	most	 noticeable	
exception	being	S2B11.	Upon	examination	of	structure	activity	
relationships	 it	 was	 observed	 that	 amongst	 the	 para‐
substituted	 derivatives	 para‐nitro	 was	 found	 to	 be	 most	
potent.	This	may	be	due	to	the	ability	of	NO2	group	to	take	part	
in	 donor‐acceptorinteractions.	 Halogens	 in	 general	 and	
chlorine	in	particular	increase	the	oral	absorption	and	potency	
of	 a	 drug	 candidate	 [45].	 Thus	 in	 addition	 to	 the	 bioactivity	
para‐chloro	 derivatives	 might	 show	 good	 oral	 absorption	 as	
well.	 Further	 structural	 optimization	 might	 lead	 to	 more	
actives.	
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Table	4.	Docking	scores	for	docking	of	S2B3	against	different	targets.	
PDB	ID	 1BNA	 1JZQ	 2RJG	 2VEG	 2ZDQ	 3TTZ	 3UDI	 1QG6	 4URM	
Docking	Score	(Kcal/mol)	 ‐7.3	 ‐8.3 ‐6.5 ‐6.6 ‐6.7 ‐6.4 ‐7.3	 ‐8.6	 ‐6.8
	
	
Table	5.	Structures	of	the	synthesized	compounds	with	binding	affinity	values	and	the	hydrogen	bonding	residues	at	the	active	site	as	predicted	by	AutoDock	
VINA.	
Compound	 Binding	affinity	(kcal/mol) No	of	H‐bonds H‐bonding	residues	
No	 R1	 R2	
S2B3	 H	 H	 ‐8.6	 01 Ile20
S2B4	 F	 H	 ‐8.8	 03 Ile20,	Ile192,	Gly93	
S2B5	 Cl	 H	 ‐8.6	 02 Ile20
S2B6	 CH3	 H	 ‐8.7	 01 Ile20
S2B7	 NO2	 H	 ‐8.6	 01 Ile20
S2B8	 OCH3	 H	 ‐8.4	 01	 Ile20	
S2B9	 H	 F	 ‐8.5	 01	 Gly199	
S2B10	 H	 Cl	 ‐8.0	 01	 Gly93	
S2B11	 H	 CH3	 ‐9.5	 01 Thr194
S2B12	 H	 NO2	 ‐8.0	 02 Thr194,	Gly93,	Tyr146	(π‐	π)	
S2B13	 H	 OCH3	 ‐8.4	 0 ‐
	
	
	
Figure	4.	(a)	Schematic	representation	for	the	docked	conformation	of	the	S2B3	at	the	active	site	of	Enoyl‐ACP	reductase	with	hydrophobic	surface,	(b)	Surface	
representation	of	the	protein	showing	the	active	site	cavity.	The	docked	ligand	binds	at	the	same	site	where	co‐crystallized	Triclosan	binds.	
	
	
	
3.4.	Molecular	docking	
	
The	aim	of	carrying	docking	study	was	to	first	predict	the	
molecular	 target	 for	 the	 synthesized	 molecules	 and	 later	
rationalize	 the	 experimental	 activity.	 The	 tested	 molecule	
S2B3	was	docked	against	nine	different	targets	with	PDB	IDs;	
1BNA,	1JZQ,	2RJG,	2VEG,	2ZDQ,	3TTZ,	3UDI,	1QG6	and	4URM	
[46‐54].	 As	 is	 evident	 from	Table	 4,	 the	 docking	 simulations	
predict	that	compound	S2B3	has	the	strongest	binding	affinity	
towards	 1QG6.	 Based	 on	 the	 docking	 score	 Enoyl‐ACP	
reductase	 was	 chosen	 as	 possible	 target	 and	 subsequently	
docking	of	 all	 synthesized	molecules	was	carried	 against	 this	
particular	target.	
Enoyl‐ACP	 reductase	 is	 a	 key	 enzyme	 for	 fatty	 acid	
biosynthesis	 in	 bacteria.	 The	 biosynthetic	 pathway	 for	 fatty	
acid	 synthesis	 in	 bacteria	 is	 pretty	 different	 from	 that	 of	
mammals.	 This	 is	 of	 great	 advantage	 in	 designing	molecules	
which	 are	 highly	 specific	 towards	 bacteria	 [55].	 Molecular	
level	understanding	of	the	extent	to	which	the	molecules	could	
inhibit	the	functioning	of	target	macromolecule	was	studied	by	
looking	 at	 the	 interactions	 involved	 between	 the	 target	 and	
inhibitor.	
Trichlosan	 (co‐crystallized	 with	 Enoyl‐ACP	 reductase)	 is	
an	 antimicrobial	 drug	 which	 is	 ineffective	 against	 resistant	
strains	 of	 E.	 coli	 because	 amino	 acids	 Gly93,	 Met159	 and	
Phe203	 are	mutated	 to	 Val,	 Thr	 and	 leu,	 respectively,	 at	 the	
active	 site.	 Therefore,	 for	 a	 drug	 to	 be	 active	 against	 the	
resistant	 strains	 of	 bacteria,	 they	 should	 be	 able	 to	 interact	
with	 the	mutated	 as	well	 as	 the	non‐mutated	 residues.	 From	
docking	studies	it	 is	clear	that	the	designed	inhibitors	bind	at	
the	 same	 site	 where	 triclosan	 binds	 (Figure	 4)	 and	 interact	
strongly	with	residues	apart	from	the	mutated	ones	(Figure	5).	
Binding	 affinity	 values	 ranging	 from	 ‐8.0	 to	 ‐9.5	 were	
predicted	for	the	designed	molecules	(Table	5).	The	prominent	
interactions	 include	 H‐bonding,	 alkyl‐π	 and	 π‐π	 stacking	
interactions.	Most	 of	 the	 inhibitors	 interact	with	 Ile20,	Gly93	
and	NAD	by	forming	strong	hydrogen	bonds.	The	formation	of	
more	than	two	H‐bonds	confers	specificity	to	the	inhibitors	for	
the	target.	The	highest	binding	affinity	is	predicted	for	S2B11	
followed	 by	 S2B4,	 S2B6	 and	 S2B7,	 respectively.	 Compound	
S2B4	 forms	 H‐bonds	 with	 Ile20,	 Ile192	 and	 Gly93.	 For	
compound	S2B12,	 Thr194	 and	Gly93	 form	H‐bonds	whereas	
Tyr146	 gets	 involved	 in	 a	 strong	π‐π	 stacking	 interaction.	 In	
conclusion	 docking	 simulations	 predict	 strong	 inhibitor‐
substrate	 interaction	 which	 is	 a	 highly	 desirable	 feature	 for	
drug	candidates.	
	
4.	Conclusions	
	
In	conclusion,	we	were	successful	in	establishing	the	initial	
hypothesis	 of	 synthesizing	 a	 novel	 class	 of	 hybrid	molecules	
with	broad	spectrum	antibiotic	activity.	As	a	starting	point,	 in	
silico	 molecular	 descriptor	 calculations	 predicted	 drug	 like	
properties	 in	 the	 synthesized	 molecules,	 which	 were	 later	
confirmed	 by	 in	 vitro	 susceptibility	 tests	 against	 some	 Gram	
positive	 and	 negative	 bacteria.	 Molecular	 docking	 studies	
predicted	 the	 molecules	 as	 Enoyl‐ACP	 reductase	 inhibitors.	
The	compounds	bind	at	the	target	site	and	get	involved	in	Van	
der	 Waals,	 H‐bonding	 and	 hydrophobic	 interactions.	 High	
binding	 affinity	 (‐8.4	 to	 ‐9.5	 kcal/mol)	was	 predicted	 for	 the	
inhibitors.	 Presence	 of	 nitro	 and	 chloro	 groups	 substantially	
increased	the	activity	of	molecules	when	present	at	meta/para	
position	 in	 the	 substituted	 phenyl	 ring.	 In	 conclusion	 the	
compounds	 we	 report	 have	 shown	 great	 promise	 for	 their	
antimicrobial	 potential.	 Further	 structural	 optimization	 may	
lead	 to	 discovery	 of	 other	 leads	 for	 antimicrobial	 drug	
discovery.		
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Figure	5.	Detailed	interactions	of	S2B4,7,	11	and	12	with	the	inhibitor	residues,	dotted	lines	represent	the	interactions.	H	bonds,	π‐π	and	alkyl‐π	interactions	
are	represented	by	green,	pink	and	violet	dotted	lines,	respectively.	
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